低密度脂蛋白胆固醇降低幅度与他汀治疗相对和绝对效应的关联:系统评价与Meta分析
该系统评价与Meta分析检索PubMed和Embase(1987年1月至2021年6月),纳入21项大型随机临床试验,比较他汀与安慰剂或常规治疗,计划随访至少2年、报告LDL-C绝对变化,受试者为18岁以上男女。结果显示他汀组全因死亡绝对风险降低0.8%(95%CI 0.4%-1.2%)、心肌梗死1.3%(95%CI 0.9%-1.7%)、卒中0.4%(95%CI 0.2%-0.6%),相对风险分别降低9%(95%CI 5%-14%)、29%(95%CI 22%-34%)、14%(95%CI 5%-22%)。探索他汀所致LDL-C降低幅度与结局关系的Meta回归结果不确定。作者认为绝对风险降低幅度较小,显著异质性降低证据确定性,LDL-C绝对降低与个体临床结局的确定性关联未建立。
要点
- 21项大型随机试验Meta分析:他汀组全因死亡绝对风险降低0.8%(95%CI 0.4%-1.2%),相对风险降低9%(95%CI 5%-14%)。
- 心肌梗死绝对风险降低1.3%(95%CI 0.9%-1.7%),相对风险降低29%(95%CI 22%-34%)。
- 卒中绝对风险降低0.4%(95%CI 0.2%-0.6%),相对风险降低14%(95%CI 5%-22%)。
- 探索他汀所致LDL-C降低幅度与结局关系的Meta回归结果不确定,LDL-C绝对降低与个体临床结局的确定性关联未建立。
- 作者认为他汀治疗的绝对风险降低幅度较小,与相对风险降低不成比例,显著异质性降低证据确定性。
适用人群与场景
- 18岁以上的男性和女性,来自计划随访至少2年、报告LDL-C绝对变化的大型随机临床试验。
研究设计与关键结果
- 系统评价与Meta分析,纳入21项大型随机临床试验,比较他汀(3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂)与安慰剂或常规治疗。
- 全因死亡绝对风险降低0.8%(95%CI 0.4%-1.2%),相对风险降低9%(95%CI 5%-14%)。
- 心肌梗死绝对风险降低1.3%(95%CI 0.9%-1.7%),相对风险降低29%(95%CI 22%-34%)。
- 卒中绝对风险降低0.4%(95%CI 0.2%-0.6%),相对风险降低14%(95%CI 5%-22%)。
- 探索他汀所致LDL-C降低幅度与结局关系的Meta回归结果不确定。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,使用偏倚风险2工具和推荐分级的评估、制定与评价(GRADE)评估方法学质量和证据确定性。
- 局限:存在显著异质性,降低证据确定性;探索他汀所致LDL-C降低幅度与结局关系的Meta回归结果不确定;LDL-C绝对降低与个体临床结局的确定性关联未建立。
对床旁实践的改变
- 作者认为,他汀治疗在全因死亡、心肌梗死和卒中方面的绝对风险降低幅度较小,与相对风险降低不成比例。
- 作者认为,与个体患者进行知情临床决策时,应讨论绝对风险降低。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The association between statin-induced reduction in low-density lipoprotein cholesterol (LDL-C) levels and the absolute risk reduction of individual, rather than composite, outcomes, such as all-cause mortality, myocardial infarction, or stroke, is unclear.
OBJECTIVE: To assess the association between absolute reductions in LDL-C levels with treatment with statin therapy and all-cause mortality, myocardial infarction, and stroke to facilitate shared decision-making between clinicians and patients and inform clinical guidelines and policy.
DATA SOURCES: PubMed and Embase were searched to identify eligible trials from January 1987 to June 2021.
STUDY SELECTION: Large randomized clinical trials that examined the effectiveness of statins in reducing total mortality and cardiovascular outcomes with a planned duration of 2 or more years and that reported absolute changes in LDL-C levels. Interventions were treatment with statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) vs placebo or usual care. Participants were men and women older than 18 years.
DATA EXTRACTION AND SYNTHESIS: Three independent reviewers extracted data and/or assessed the methodological quality and certainty of the evidence using the risk of bias 2 tool and Grading of Recommendations, Assessment, Development and Evaluation. Any differences in opinion were resolved by consensus. Meta-analyses and a meta-regression were undertaken.
MAIN OUTCOMES AND MEASURES: Primary outcome: all-cause mortality. Secondary outcomes: myocardial infarction, stroke.
FINDINGS: Twenty-one trials were included in the analysis. Meta-analyses showed reductions in the absolute risk of 0.8% (95% CI, 0.4%-1.2%) for all-cause mortality, 1.3% (95% CI, 0.9%-1.7%) for myocardial infarction, and 0.4% (95% CI, 0.2%-0.6%) for stroke in those randomized to treatment with statins, with associated relative risk reductions of 9% (95% CI, 5%-14%), 29% (95% CI, 22%-34%), and 14% (95% CI, 5%-22%) respectively. A meta-regression exploring the potential mediating association of the magnitude of statin-induced LDL-C reduction with outcomes was inconclusive.
CONCLUSIONS AND RELEVANCE: The results of this meta-analysis suggest that the absolute risk reductions of treatment with statins in terms of all-cause mortality, myocardial infarction, and stroke are modest compared with the relative risk reductions, and the presence of significant heterogeneity reduces the certainty of the evidence. A conclusive association between absolute reductions in LDL-C levels and individual clinical outcomes was not established, and these findings underscore the importance of discussing absolute risk reductions when making informed clinical decisions with individual patients.
参考来源
- Byrne P, Demasi M, Jones M, et al. Evaluating the Association Between Low-Density Lipoprotein Cholesterol Reduction and Relative and Absolute Effects of Statin Treatment: A Systematic Review and Meta-analysis. JAMA Intern Med. 2022. PMID: 35285850. doi:10.1001/jamainternmed.2022.0134
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。